SEC filing record
Primary Source · SEC.gov

Applied Therapeutics, Inc.

2024 vintageSecurities Exchange Act of 1934Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalExchange Act deregistrationForm 15-12G · 2026-02-132 events: 1 exchange act deregistration, 1 new form d filerLast filing 2026-02-13

Raised

$100M

Investors

31

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Applied Therapeutics, Inc. is an entity organized in Delaware that filed a Form D with the SEC on February 13, 2026. The offering claims Securities Exchange Act of 1934. Applied Therapeutics, Inc. reported $99,997,998 sold from 31 investors as of the Form D filed February 13, 2026. The Form D names UBS Securities LLC (CRD 7654), associated with None; Leerink Partners LLC (CRD 39011), associated with None; RBC Capital Markets, LLC (CRD 31194), associated with None; Robert W. Baird & Co. Inc. (CRD 8158), associated with None as recipients of sales compensation soliciting in CA, CO, CT, FL, IL, MA, MD, NJ, NY, PA, UT. The issuer's address of record is 545 Fifth Avenue, Suite 1400, New York, NY 10017.

EDGAR Filing Data

Form 15 / Schedule TO — Primary Source

View on SEC.gov
CIK Number0001697532
Entity NameApplied Therapeutics, Inc.
ExemptionSecurities Exchange Act of 1934
Entity Type—
Jurisdiction of OrganizationDelaware
Issuer Address545 Fifth Avenue, Suite 1400, New York, NY 10017
Phone(212) 220-9226
Former NamesApplied Therapeutics Inc. (until March 11, 2024)
Industry / Fund Type—
Securities Type—
First Sale Date—
Filing DateFebruary 13, 2026
Accession Number0001193125-26-049942
Total Offering Amount$99,997,998
Total Amount Sold$99,997,998
Total Investors31
Minimum Investment$0 (no stated minimum)
Offering Duration—
State (Issuer Address)NY
Amendment Count7 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

2

latest Feb 13, 2026

Critical / warning

0 / 1

1 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

6

lapsed, closed

Latest event Exchange act deregistration · Feb 13, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 2 filing events with values and deltas, latest 2026-02-13, and alerts on the next one
  • 6 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-03-13: 1 related person added and 0 removed against the filing of 2023-05-05; 9 now listed. The names are in the Terminal feed.

Shoshana Shendelman

Executive Officer, Director · New York, NY

President and Chief Executive Officer

Riccardo Perfetti

Executive Officer · New York, NY

Chief Medical Officer

Adam Hansard

Executive Officer · New York, NY

Chief Commercial Officer

Les Funtleyder

Executive Officer, Director · New York, NY

Chief Financial Officer and Director

Catherine Thorpe

Executive Officer · New York, NY

Chief Accounting Officer

Stacy J. Kanter

Director · New York, NY

Teena J. Lerner

Director · New York, NY

Joel S. Marcus

Director · New York, NY

Jay S. Skyler

Director · New York, NY

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

UBS Securities LLCCRD 7654 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in CA, CO, CT, FL, IL, MA, MD, NJ, NY, PA, UT

Leerink Partners LLCCRD 39011 on BrokerCheck

Associated broker-dealer: None · Boston, MA · Soliciting in CA, CO, CT, FL, IL, MA, MD, NJ, NY, PA, UT

RBC Capital Markets, LLCCRD 31194 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in CA, CO, CT, FL, IL, MA, MD, NJ, NY, PA, UT

Robert W. Baird & Co. Inc.CRD 8158 on BrokerCheck

Associated broker-dealer: None · Milwaukee, WI · Soliciting in CA, CO, CT, FL, IL, MA, MD, NJ, NY, PA, UT

Questions About Applied Therapeutics, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Applied Therapeutics, Inc.?

Applied Therapeutics, Inc. is an issuer that filed a Form D with the SEC on February 13, 2026. The filing claims Securities Exchange Act of 1934.

Is Applied Therapeutics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Applied Therapeutics, Inc. filed a Form D with the SEC on February 13, 2026 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $99,997,998 sold to 31 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Applied Therapeutics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Applied Therapeutics, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Applied Therapeutics, Inc. raised?

Applied Therapeutics, Inc. reported $99,997,998 sold from 31 investors as of the Form D filed February 13, 2026.

Who is selling Applied Therapeutics, Inc. and how are they paid?

The Form D names UBS Securities LLC (CRD 7654), associated with None; Leerink Partners LLC (CRD 39011), associated with None; RBC Capital Markets, LLC (CRD 31194), associated with None; Robert W. Baird & Co. Inc. (CRD 8158), associated with None as recipients of sales compensation soliciting in CA, CO, CT, FL, IL, MA, MD, NJ, NY, PA, UT.

Who is behind Applied Therapeutics, Inc.?

The Form D lists 9 related persons: Shoshana Shendelman, executive officer, director (President and Chief Executive Officer); Riccardo Perfetti, executive officer (Chief Medical Officer); Adam Hansard, executive officer (Chief Commercial Officer); Les Funtleyder, executive officer, director (Chief Financial Officer and Director); Catherine Thorpe, executive officer (Chief Accounting Officer); Stacy J. Kanter, director; Teena J. Lerner, director; Joel S. Marcus, director, and 1 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Applied Therapeutics, Inc. located?

The issuer's address on its SEC filings is 545 Fifth Avenue, Suite 1400, New York, NY 10017. Its phone number of record is 212-220-9226. It is organized under the laws of Delaware.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.